Imaging test for neuroblastoma using a PET scan with 18F-MFBG
Tests a PET scan tracer in children with neuroblastoma, a cancer.
Plain-language title generated from the registry record
Registry title: 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Key facts
- Where
- Hangzhou, ChinaSee the site
Where in China
- The First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Zhejiang University
- Trial code
- NCT06852807
- Record updated
- 8 August 2025
- Original description
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.Read full original descriptionShow less
Prospective Clinical Study of 18F-mFBG PET Imaging in Neuroblastoma
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
Inclusion: Age 0-18 years old, with legal guardian; Clinically suspected or confirmed patients with neuroblastoma; If the patient is under 8 years old or unable to write, his/her guardian should understand and comply with the requirements of the study. If the patient is 8 years old or older and has written ability, both the patient and his/her guardian must sign the informed consent.
Exclusion: Patients who have received ionizing radiation outside the scope of this experiment for other clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv; Patients who have received experimental drugs or devices (with uncertain efficacy or safety) within one month; Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system diseases; Patients with any condition that the principal investigator of this study deems may cause harm or potential harm in any aspect related to this trial.